The benefits of remdesivir treatment, with or without co-administration of antibiotics such as
azithromycin, are uncertain in COVID-19 pneumonia. The aim of this retrospective single …

Aim To evaluate the association of remdesivir use and the survival of hospitalized patients
with coronavirus disease 2019 (COVID-19). Methods We retrospectively reviewed the …

Introduction Remdesivir exerts positive effects on clinical improvement, even though it
seems not to affect mortality among COVID-19 patients; moreover, it was associated with the …

Remdesivir (RDV) was the first Food and Drug Administration (FDA)-approved medication
for COVID-19, with discordant data on efficacy in reducing mortality risk and disease …

In several randomized studies, remdesivir (RDV) has been reported to shorten the recovery
period and improve clinical outcomes in COVID-19 patients, and thus, it is recommended as …

Purpose Preliminary data suggest that remdesivir may influence the course of COVID-19
according to the duration of pre-admission symptoms. We aim to evaluate whether early use …

Phase 3 trials showed that remdesivir, administered to adult patients hospitalized for SARS-
CoV-2-related pneumonia, both as 10-day (Beigel et al., 2020) and 5-day course (Goldman …

Background Remdesivir has been associated with accelerated recovery of severe
coronavirus disease 2019 (COVID-19). However, whether it is also beneficial in patients …

The aim of this study is to describe the features, the outcomes, and the clinical issues related
to Remdesivir administration of a cohort of 220 patients (pts) with COVID-19 hospitalized …

Background Remdesivir is a prodrug with in vitro activity against severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2). Its clinical efficacy in patients with COVID-19 under …